| Literature DB >> 33709283 |
Sahar A Al Shabasy1, Maggie M Abbassi1, Aureliano Paolo Finch2, Darrin Baines3, Samar F Farid4.
Abstract
INTRODUCTION: No value sets exist for either the EQ-5D-3L or the EQ-5D-5L in Egypt, despite local pharmacoeconomic guidelines recommending the use of the EQ-5D to derive utility. Most published Egyptian economic evaluation studies have used utility values from other published studies and systematic reviews.Entities:
Year: 2021 PMID: 33709283 PMCID: PMC7952144 DOI: 10.1007/s40273-021-01002-z
Source DB: PubMed Journal: Pharmacoeconomics ISSN: 1170-7690 Impact factor: 4.981
Background characteristics of the Egyptian participants
| Characteristics | Full sample ( | Actual sample ( | General populationa | |
|---|---|---|---|---|
| Sex | ||||
| Male | 672 (51.6) | 510 (52.4) | 51.6 | 0.617 |
| Female | 631 (48.4) | 464 (47.6) | 48.4 | 0.617 |
| Age (years) | 35.8 ± 12.8 (18–75) | 36.9 ± 12.7 (18–72) | – | – |
| 18–24 | 317 (24.3) | 213 (21.9) | 18.8 | 0.013* |
| 25–34 | 363 (27.9) | 237 (24.3) | 27.9 | 0.042* |
| 35–44 | 279 (21.4) | 236 (24.2) | 20.9 | 0.003* |
| 45–54 | 212 (16.3) | 184 (18.9) | 15.1 | <0.001* |
| 55–64 | 110 (8.4) | 90 (9.2) | 10.6 | 0.156 |
| ≥ 65 | 22 (1.7) | 14 (1.4) | 6.6 | <0.001* |
| Geographical region b | ||||
| Greater Cairo | 511 (39.3) | 256 (26.3) | 25.1 | 0.390 |
| Alexandria | 123 (9.5) | 119 (12.2) | 12.4 | 0.849 |
| Delta | 229 (17.6) | 202 (20.8) | 21.7 | 0.497 |
| Suez Canal | 123 (9.5) | 114 (11.7) | 11.2 | 0.624 |
| North upper Egypt | 144 (11.1) | 122 (12.6) | 12.9 | 0.779 |
| Asyut | 45 (3.5) | 44 (4.5) | 4.9 | 0.561 |
| South upper Egypt | 126 (9.7) | 115 (11.8) | 11.8 | 1 |
| Residenceb | ||||
| Urban | 934 (71.8) | 658 (67.7) | 42.2 | <0.001* |
| Rural | 367 (28.2) | 314 (32.3) | 57.8 | <0.001* |
| Education level b | ||||
| Illiterate | 116 (8.9) | 109 (11.2) | 25.8 | <0.001* |
| Below intermediate c | 311 (23.9) | 290 (29.8) | 29.0 | 0.833 |
| Intermediated | 511 (39.3) | 398 (40.9) | 29.1 | <0.001* |
| University degree and above | 363 (27.9) | 175 (18) | 15.5 | <0.001* |
| Employment status b | ||||
| Employed | 950 (73) | 728 (74.9) | 74.4 | 0.721 |
| Unemployed/retired/students/other | 351 (27) | 244 (25.1) | 25.6 | 0.721 |
| Marital status b | ||||
| Married | 740 (56.8) | 602 (61.9) | 68 | <0.001* |
| Single/divorced/widowed | 561 (43.2) | 370 (38.1) | 32 | <0.001* |
| Religious beliefs b | ||||
| Muslim | 1241 (95.4) | 931 (95.8) | 94.9 e | 0.202 |
| Christian | 60 (4.6) | 41 (4.2) | 5.1 | 0.202 |
| Presence of chronic health condition b | 414 (31.8) | 285 (29.3) | - | - |
| Health insurance b | ||||
| Covered (full or partial) | 786 (60.4) | 579 (59.6) | 54.7 | 0.0021* |
| No coverage | 515 (39.6) | 393 (40.4) | 45.3 | 0.0019* |
| VAS-5L scores | 77.5 ± 16.2 | 76.9 ± 16.7 | ||
| Mobility | ||||
| No problems | 893 (68.5) | 664 (68.2) | ||
| Slight problems | 234 (18) | 169 (17.4) | ||
| Moderate problems | 136 (10.4) | 107 (11) | ||
| Severe problems | 39 (3) | 34 (3.5) | ||
| Unable to walk | 1 (0.1) | 0 (0) | ||
| Self-care | ||||
| No problems | 1226 (94.1) | 912 (93.6) | ||
| Slight problems | 52 (4) | 40 (4.1) | ||
| Moderate problems | 17 (1.3) | 15 (1.5) | ||
| Severe problems | 8 (0.6) | 7 (0.7) | ||
| Unable to dress and wash | 0 (0) | 0 (0) | ||
| Usual activities | ||||
| No problems | 891 (68.4) | 667 (68.5) | ||
| Slight problems | 252 (19.3) | 183 (18.8) | ||
| Moderate problems | 132 (10.1) | 100 (10.3) | ||
| Severe problems | 24 (1.8) | 21 (2.2) | ||
| Unable to do usual activities | 4 (0.3) | 3 (0.3) | ||
| Pain/discomfort | ||||
| No problems | 510 (39.1) | 386 (39.6) | ||
| Slight problems | 436 (33.5) | 302 (31) | ||
| Moderate problems | 284 (21.8) | 219 (22.5) | ||
| Severe problems | 52 (4) | 48 (4.9) | ||
| Extreme pain or discomfort | 21 (1.6) | 19 (2) | ||
| Anxiety/depression | ||||
| No problems | 420 (32.2) | 348 (35.7) | ||
| Slight problems | 410 (31.5) | 287 (29.5) | ||
| Moderate problems | 343 (26.3) | 232 (23.8) | ||
| Severe problems | 76 (5.8) | 61 (6.3) | ||
| Extreme anxiety or depression | 54 (4.1) | 46 (4.7) |
Data are presented as n (%), mean ± standard deviation (range), or % unless otherwise indicated
VAS visual analogue scale
*p<0.05 (based on 1-sample z-test for a population proportion)
aData estimated from the Egyptian Central Agency for Public Mobilization and Statistics, March 2019[11]
bSample size was n=1301 for the full sample and n=972 for the actual sample
cBelow intermediate: below high school level
dIntermediate: high school level or 2 years institute
eData obtained from Mohamoud et al.[30]
Fig. 1Observed (composite time trade-off [cTTO]) value distribution
Fig. 2Mean observed composite time trade-off value by level of sum scores. cTTO composite time trade-off, SD standard deviation
Parameter estimates for composite time trade-off models
| Dimension/level | Model 1 | Model 2 | Model 3 | Model 4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLS (random-effect model) | GLS Tobit (random effect, censored at − 1) | Heteroskedastic Tobit (random effect, censored at − 1 with heteroskedasticity) | Heteroskedastic model (heteroskedasticity of the error term) (value set) | |||||||||
| Coeff. | SE | Coeff. | SE | Coeff. | SE | Coeff. | SE | |||||
| Mobility (MO) | ||||||||||||
| Disutility MO1–MO2 | 0.084 | 0.015 | 0.000 | 0.068 | 0.016 | 0.000 | 0.028 | 0.012 | 0.023 | 0.068 | 0.014 | 0.000 |
| Disutility MO1–MO3 | 0.202 | 0.016 | 0.000 | 0.171 | 0.017 | 0.000 | 0.08 | 0.02 | 0.000 | 0.232 | 0.02 | 0.000 |
| Disutility MO1–MO4 | 0.409 | 0.017 | 0.000 | 0.386 | 0.019 | 0.000 | 0.305 | 0.021 | 0.000 | 0.4 | 0.021 | 0.000 |
| Disutility MO1–MO5 | 0.618 | 0.016 | 0.000 | 0.659 | 0.017 | 0.000 | 0.657 | 0.019 | 0.000 | 0.595 | 0.017 | 0.000 |
| Self-care (SC) | ||||||||||||
| Disutility SC1–SC2 | 0.031 | 0.015 | 0.034 | 0.029 | 0.016 | 0.074 | 0.022 | 0.012 | 0.052 | 0.054 | 0.013 | 0.000 |
| Disutility SC1–SC3 | 0.106 | 0.017 | 0.000 | 0.105 | 0.018 | 0.000 | 0.096 | 0.017 | 0.000 | 0.111 | 0.018 | 0.000 |
| Disutility SC1–SC4 | 0.243 | 0.017 | 0.000 | 0.241 | 0.018 | 0.000 | 0.236 | 0.019 | 0.000 | 0.249 | 0.019 | 0.000 |
| Disutility SC1–SC5 | 0.253 | 0.015 | 0.000 | 0.316 | 0.017 | 0.000 | 0.439 | 0.019 | 0.000 | 0.278 | 0.017 | 0.000 |
| Usual activities (UA) | ||||||||||||
| Disutility UA1–UA2 | 0.045 | 0.015 | 0.003 | 0.04 | 0.016 | 0.016 | 0.023 | 0.011 | 0.043 | 0.047 | 0.013 | 0.000 |
| Disutility UA1–UA3 | 0.075 | 0.016 | 0.000 | 0.072 | 0.018 | 0.000 | 0.075 | 0.017 | 0.000 | 0.074 | 0.019 | 0.000 |
| Disutility UA1–UA4 | 0.221 | 0.016 | 0.000 | 0.22 | 0.018 | 0.000 | 0.241 | 0.018 | 0.000 | 0.25 | 0.018 | 0.000 |
| Disutility UA1–UA5 | 0.24 | 0.015 | 0.000 | 0.299 | 0.017 | 0.000 | 0.383 | 0.02 | 0.000 | 0.206 | 0.018 | 0.000 |
| Pain/discomfort (PD) | ||||||||||||
| Disutility PD1–PD2 | 0.045 | 0.014 | 0.001 | 0.033 | 0.015 | 0.026 | 0.023 | 0.01 | 0.025 | 0.047 | 0.012 | 0.000 |
| Disutility PD1–PD3 | 0.076 | 0.017 | 0.000 | 0.071 | 0.018 | 0.000 | 0.074 | 0.02 | 0.000 | 0.107 | 0.02 | 0.000 |
| Disutility PD1–PD4 | 0.244 | 0.015 | 0.000 | 0.261 | 0.016 | 0.000 | 0.29 | 0.018 | 0.000 | 0.273 | 0.018 | 0.000 |
| Disutility PD1–PD5 | 0.363 | 0.016 | 0.000 | 0.412 | 0.018 | 0.000 | 0.509 | 0.021 | 0.000 | 0.436 | 0.02 | 0.000 |
| Anxiety/depression (AD) | ||||||||||||
| Disutility AD1–AD2 | 0.048 | 0.016 | 0.002 | 0.041 | 0.017 | 0.018 | 0.035 | 0.01 | 0.001 | 0.051 | 0.012 | 0.000 |
| Disutility AD1–AD3 | 0.158 | 0.018 | 0.000 | 0.139 | 0.02 | 0.000 | 0.135 | 0.02 | 0.000 | 0.193 | 0.02 | 0.000 |
| Disutility AD1–AD4 | 0.298 | 0.016 | 0.000 | 0.296 | 0.018 | 0.000 | 0.337 | 0.018 | 0.000 | 0.336 | 0.018 | 0.000 |
| Disutility AD1–AD5 | 0.4 | 0.015 | 0.000 | 0.444 | 0.017 | 0.000 | 0.527 | 0.017 | 0.000 | 0.412 | 0.016 | 0.000 |
| Constant | 0.037 | 0.018 | 0.037 | 0.037 | 0.02 | 0.064 | 0.024 | 0.011 | 0.000 | 0.007 | 0.012 | 0.545 |
| Dimension ranking | MO-AD-PD-SC-UA | MO-AD-PD-SC-UA | MO-AD-PD-SC-UA | MO-PD-AD-SC-UA | ||||||||
| Insignificant | 0 | 1 | 1 | 0 | ||||||||
| Illogically ordered | 0 | 0 | 0 | 0 | ||||||||
| AIC | 10282.88 | 12203.67 | 12419.71 | 11093.54 | ||||||||
| BIC | 10445.88 | 12366.68 | 12717.38 | 11391.21 | ||||||||
| MAE | 0.364 | 0.374 | 0.410 | 0.362 | ||||||||
| RMSE | 0.482 | 0.491 | 0.536 | 0.484 | ||||||||
| 55555 | − 0.912 | − 1.168 | − 1.515 | − 0.933 | ||||||||
AIC Akaike information criteria, BIC Bayesian information criteria, Coeff coefficient, GLS generalized least square, MAE mean absolute error, RMSE root mean square error, SE standard error
Parameter estimates for discrete-choice experiment model
| Dimension/level | Model 5 | |||
|---|---|---|---|---|
| Conditional logit model | ||||
| Beta | Rescaled Beta | SE | ||
| Mobility (MO) | ||||
| Disutility MO1–MO2 | 0.266 | 0.069 | 0.058 | 0.000 |
| Disutility MO1–MO3 | 0.36 | 0.093 | 0.067 | 0.000 |
| Disutility MO1–MO4 | 1.13 | 0.291 | 0.072 | 0.000 |
| Disutility MO1–MO5 | 2.286 | 0.587 | 0.09 | 0.000 |
| Self-care (SC) | ||||
| Disutility SC1–SC2 | 0.241 | 0.062 | 0.065 | 0.000 |
| Disutility SC1–SC3 | 0.237 | 0.061 | 0.069 | 0.001 |
| Disutility SC1–SC4 | 0.783 | 0.202 | 0.071 | 0.000 |
| Disutility SC1–SC5 | 1.5 | 0.386 | 0.074 | 0.000 |
| Usual activities (UA) | ||||
| Disutility UA1–UA2 | 0.277 | 0.071 | 0.06 | 0.000 |
| Disutility UA1–UA3 | 0.261 | 0.067 | 0.069 | 0.000 |
| Disutility UA1–UA4 | 0.837 | 0.215 | 0.07 | 0.000 |
| Disutility UA1–UA5 | 1.548 | 0.399 | 0.076 | 0.000 |
| Pain/discomfort (PD) | ||||
| Disutility PD1–PD2 | 0.18 | 0.046 | 0.064 | 0.005 |
| Disutility PD1–PD3 | 0.273 | 0.07 | 0.069 | 0.000 |
| Disutility PD1–PD4 | 0.734 | 0.189 | 0.069 | 0.000 |
| Disutility PD1–PD5 | 1.435 | 0.369 | 0.075 | 0.000 |
| Anxiety/depression (AD) | ||||
| Disutility AD1–AD2 | 0.08 | 0.02 | 0.065 | 0.222 |
| Disutility AD1–AD3 | 0.25 | 0.064 | 0.067 | 0.000 |
| Disutility AD1–AD4 | 0.823 | 0.212 | 0.074 | 0.000 |
| Disutility AD1–AD5 | 1.529 | 0.394 | 0.082 | 0.000 |
| Ranking of dimensions | MO-UA-AD-SC-PD | |||
| Insignificant | 1 | |||
| Illogically ordered | 2 | |||
| AIC | 6776.675 | |||
| BIC | 6913.222 | |||
| 55555 | − 1.135 | |||
AIC Akaike information criteria, BIC Bayesian information criteria, SE standard error
Parameter estimates for hybrid models
| Dimension/level | Model 6 | Model 7 | Model 8 | Model 9 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hybrid (random-effect, conditional logit model) | Hybrid Tobit (random-effect, censored at -1, conditional logit model) | Hybrid heteroskedastic Tobit (random-effect, censored at -1 with heteroskedasticity, conditional logit model) | Hybrid heteroskedastic model | |||||||||
| Coeff. | SE | Coeff. | SE | Coeff. | SE | Coeff. | SE | |||||
| Mobility (MO) | ||||||||||||
| Disutility MO1–MO2 | 0.1 | 0.011 | 0.000 | 0.089 | 0.012 | 0.000 | 0.055 | 0.009 | 0.000 | 0.085 | 0.009 | 0.000 |
| Disutility MO1–MO3 | 0.142 | 0.012 | 0.000 | 0.126 | 0.013 | 0.000 | 0.104 | 0.014 | 0.000 | 0.139 | 0.012 | 0.000 |
| Disutility MO1–MO4 | 0.348 | 0.012 | 0.000 | 0.34 | 0.013 | 0.000 | 0.342 | 0.014 | 0.000 | 0.341 | 0.012 | 0.000 |
| Disutility MO1–MO5 | 0.583 | 0.012 | 0.000 | 0.621 | 0.013 | 0.000 | 0.709 | 0.014 | 0.000 | 0.586 | 0.012 | 0.000 |
| Self-care (SC) | ||||||||||||
| Disutility SC1–SC2 | 0.063 | 0.011 | 0.000 | 0.06 | 0.012 | 0.000 | 0.045 | 0.008 | 0.000 | 0.062 | 0.009 | 0.000 |
| Disutility SC1–SC3 | 0.09 | 0.012 | 0.000 | 0.081 | 0.013 | 0.000 | 0.082 | 0.013 | 0.000 | 0.089 | 0.012 | 0.000 |
| Disutility SC1–SC4 | 0.245 | 0.012 | 0.000 | 0.238 | 0.013 | 0.000 | 0.242 | 0.014 | 0.000 | 0.242 | 0.012 | 0.000 |
| Disutility SC1–SC5 | 0.333 | 0.011 | 0.000 | 0.38 | 0.012 | 0.000 | 0.456 | 0.013 | 0.000 | 0.349 | 0.011 | 0.000 |
| Usual activities (UA) | ||||||||||||
| Disutility UA1–UA2 | 0.082 | 0.011 | 0.000 | 0.076 | 0.012 | 0.000 | 0.045 | 0.008 | 0.000 | 0.065 | 0.009 | 0.000 |
| Disutility UA1–UA3 | 0.095 | 0.012 | 0.000 | 0.092 | 0.013 | 0.000 | 0.073 | 0.013 | 0.000 | 0.092 | 0.012 | 0.000 |
| Disutility UA1–UA4 | 0.236 | 0.012 | 0.000 | 0.244 | 0.013 | 0.000 | 0.247 | 0.013 | 0.000 | 0.239 | 0.012 | 0.000 |
| Disutility UA1–UA5 | 0.342 | 0.011 | 0.000 | 0.395 | 0.012 | 0.000 | 0.442 | 0.013 | 0.000 | 0.337 | 0.011 | 0.000 |
| Pain/discomfort (PD) | ||||||||||||
| Disutility PD1–PD2 | 0.059 | 0.011 | 0.000 | 0.052 | 0.011 | 0.000 | 0.039 | 0.008 | 0.000 | 0.054 | 0.008 | 0.000 |
| Disutility PD1–PD3 | 0.087 | 0.012 | 0.000 | 0.087 | 0.013 | 0.000 | 0.077 | 0.014 | 0.000 | 0.103 | 0.012 | 0.000 |
| Disutility PD1–PD4 | 0.23 | 0.012 | 0.000 | 0.244 | 0.013 | 0.000 | 0.263 | 0.014 | 0.000 | 0.239 | 0.012 | 0.000 |
| Disutility PD1–PD5 | 0.341 | 0.012 | 0.000 | 0.396 | 0.013 | 0.000 | 0.475 | 0.015 | 0.000 | 0.37 | 0.012 | 0.000 |
| Anxiety/depression (AD) | ||||||||||||
| Disutility AD1–AD2 | 0.06 | 0.011 | 0.000 | 0.059 | 0.012 | 0.000 | 0.042 | 0.007 | 0.000 | 0.055 | 0.008 | 0.000 |
| Disutility AD1–AD3 | 0.137 | 0.012 | 0.000 | 0.125 | 0.013 | 0.000 | 0.114 | 0.014 | 0.000 | 0.133 | 0.012 | 0.000 |
| Disutility AD1–AD4 | 0.267 | 0.012 | 0.000 | 0.282 | 0.012 | 0.000 | 0.293 | 0.013 | 0.000 | 0.276 | 0.011 | 0.000 |
| Disutility AD1–AD5 | 0.395 | 0.012 | 0.000 | 0.436 | 0.012 | 0.000 | 0.507 | 0.014 | 0.000 | 0.399 | 0.011 | 0.000 |
| Dimension ranking | MO-UA-PD-AD-SC | MO-AD-PD-UA-SC | MO-AD-PD-SC-UA | MO-AD-PD-SC-UA | ||||||||
| Insignificant | 0 | 0 | 0 | 0 | ||||||||
| Illogically ordered | 0 | 0 | 0 | 0 | ||||||||
| AIC | 19232.64 | 21297.46 | 19207.84 | 18103.23 | ||||||||
| BIC | 19401.14 | 21465.95 | 19529.51 | 18424.9 | ||||||||
| MAE | 0.362216 | 0.382768 | 0.416236 | 0.363773 | ||||||||
| RMSE | 0.485575 | 0.497105 | 0.543049 | 0.486582 | ||||||||
| 55555 | − 0.997 | − 1.229 | − 1.575 | − 1.047 | ||||||||
AIC Akaike information criteria, BIC Bayesian information criteria, Coeff coefficient, MAE mean absolute error, RMSE root mean square error, SE standard error
Fig. 3Scatterplots of the predicted values of the heteroskedastic model versus observed values of composite time trade-off
| This is the first EQ-5D-5L valuation study in Egypt and in the Middle East and North Africa region. |
| The Egyptian tariff can be used as a scoring system for economic evaluations, to inform decision making, and to improve the quality of health technology assessment in the Egyptian healthcare system. |
| The availability of the Egyptian tariff will encourage health economists and clinicians to include quality-of-life questionnaires in clinical trials and implement cost-utility analysis and pharmacoeconomic modelling. |